Search

Background: The Assessment of Spondyloarthritis international Society Health Index (ASAS HI) has been develop and validated to assess health and function in patients with spondyloarthritis. However, whether ASAS HI differs between men and women is unknown. The aim of this study was to compare ASAS HI between men ans women in patients with ankylosing spondylitis (AS). Objectives: The aim of this study was to compare ASAS HI between men ans women in patients with ankylosing spondylitis (AS). Methods: Since November 2016, we measured and recorded data of demography, comorbidity, family history, medication use, the Ankylosing Spondylitis Disease Activity Score (ASDAS), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI), the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) and the ASAS HI for AS patients in clinical practice using an electronic patient reported data system linked to an electronic medical record system in Taichung Veterans General hospital (TCVGH). We retrieved the last recorded data of AS patients in TCVGH during 2017/11–2018/10. We assessed the association between gender and the ASAS HI using a multivariable linear regression model. Variables from the univariable linear regression analysis with p Results: A total of 307 AS patients [62 (20.2%) females, mean age 46.4 years (S.D. 13.3), mean symptom duration 20.6 years (S.D. 12.1)] were included. Female patients had an older age at onset (29.2 ± 12.6 vs 24.9 ± 9.6 years, p = 0.015), a shorter symptom duration (15.7 ± 11.6 vs 21.8 ± 12.0 years, p Conclusion: This single center, cross-sectional study revealed that male gender was significantly associated with lower ASAS HI in AS patients. Reference: [1] Kiltz U, van der Heijde D, Boonen A, Akkoc N, Bautista-Molano W, et al. 2018. Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Annals of the rheumatic diseases 77:1311-7. Disclosure of Interests: Hsin-Hua Chen Speakers bureau: Johnson & Johnson, Novartis, Pfizer, Abbvie, Roche, UCB, Bristol-Myers Squibb, Chugai, Ting-I Pan: None declared, Yi-Ming Chen Grant/research support from: GSK, Pfizer, BMS, Astra & Zeneca, Consultant for: Pfizer, Novartis, Abbvie, Johnson & Johnson, BMS, Roche, Sanofi, MSD, Guigai, Astellas Inova Diagnostics, UCB Agnitio Science Technology, United Biopharma, Thermo Fisher, Paid instructor for: Pfizer, Novartis, Abbvie, Johnson & Johnson, BMS, Roche, Astra& Zeneca, Sanofi, MSD, Guigai, Astellas UCB Thermo Fisher, Speakers bureau: Pfizer, Novartis, Abbvie, Johnson & Johnson, BMS, Roche, Lilly, GSK, Astra& Zeneca, Sanofi, MSD, Guigai, Astellas UCB Thermo Fisher, Kuo-Lung Lai: None declared, Tsu-Yi Hsieh: None declared, Ching-Tsai Lin: None declared, Wei-Ting Hung: None declared, Yin-Yi Chou: None declared, Chih-Wei Tseng: None declared, Yi-Da Wu: None declared, Chia-Wei Hsieh: None declared, Wen-Nan Huang: None declared, Yi-Hsing Chen: None declared, Der-Yuan Chen: None declared

Background: The Bath ankylosing Spondylitis Disease activity index (BASDAI) has been widely utilized to evaluate disease activity in patients with ankylosing spondylitis (AS). However, the cut-off of BASDAI used to indicate high disease activity (i.e., ≥4) was determined arbitrarily and was suggested as a criterion to initiate biological therapy for aS patients. The ankylosing Spondylitis Disease activity Score (ASDAS) has been developed as a new composite index to assess aS disease activity. The cut-off values for disease activity states has been defined and validated. ASDAS≥2.1 was selected as a criterion of starting biological therapy. However, the BASDAI cut-off values corresponding to the aSDAS cut-off values for disease activity states were unknown. Objectives: The purpose of this study was to estimate the corresponding BASDAI and aSDAS cut-off in a Taiwanese aS cohort. Methods: Since November 2016, we assessed the ankylosing Spondylitis Disease activity Score (ASDAS) and the Bath ankylosing Spondylitis Disease activity index (BASDAI) regularly and recorded demographic data, comorbidity, family history, medication use for aS patients in Taichung Veterans General hospital (TCVGH) using an electronic patient reported data system linked to an electronic medical record system. We identified 489 aS patients with complete baseline demographic and assessment data from the TCVGH electronic data system during 2016/11–2018/10. We used receiver operating characteristic (ROC) curves with Youden’s J statistic to determine the cut-off values of BASDAI that correspond to aSDAS disease activity cut-offs (i.e., 1.3, 2.1 and 3.5). Results: We included a total of 489 aS patients [114 (23.3%) females, mean age 44.1 years (S.D. 13.9), mean symptom duration 18.0 years (S.D. 11.9), 152 (31.1%) current biologic users]. Mean BASDAI, aSDAS-ESR and aSDAS-CRP scores were 2.1 (S.D. 1.5), 1.6 (S.D. 0.8) and 1.5 (S.D. 0.9) respectively. Mean levels of CRP and ESR were 0.6 (S.D. 1.5) mg/dl and 12.2 (S.D. 14.0) mm/hr respectively. Based on aSDAS-CRP, the numbers (%) of aS patients with inactive disease ( Conclusion: The estimated optimal BASDAI value that corresponds to the recommended aSDAS cut-off ≥2.1 for biologial therapy initiation was lower than the recommended BASDAI cut-off of ≥4 in this Taiwanese aS cohort. References [1] Machado P, et al. 2011. Ankylosing Spondylitis Disease activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis2011;70:47-53. Disclosure of interests: Hsin-Hua Chen Speakers bureau: Johnson & Johnson, Novartis, Pfizer, abbvie, Roche, UCB, Bristol-Myers Squibb, Chugai, Ting-I Pan: None declared, Yi-Ming Chen Grant/research support from: GSK, Pfizer, BMS, astra & Zeneca, Consultant for: Pfizer, Novartis, abbvie, Johnson & Johnson, BMS, Roche, Sanofi, MSD, Guigai, astellas, inova Diagnostics, UCB, agnitio Science Technology, United Biopharma, thermo Fisher, Paid instructor for: Pfizer, Novartis, abbvie, Johnson & Johnson, BMS, Roche, astra& Zeneca, Sanofi, MSD, Guigai, astellas, UCB, thermo Fisher, Speakers bureau: Pfizer, Novartis, abbvie, Johnson & Johnson, BMS, Roche, Lilly, GSK, astra& Zeneca, Sanofi, MSD, Guigai, astellas, UCB, thermo Fisher, Yi-Hsing Chen: None declared, Wen-Nan Huang: None declared, Tsu-Yi Hsieh: None declared, Kuo-Lung Lai: None declared, Wei-Ting Hung: None declared, Yin-Yi Chou: None declared, Chih-Wei Tseng: None declared, Yi-Da Wu: None declared, Chia-Wei Hsieh: None declared, Ching-Tsai Lin: None declared